Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer

Table 3 Scenario analysis results

Scenario	Strategy	Cost	Incr Cost	Eff	Incr Eff	ICER	Remarks
1	Chemotherapy	2734.55		2.73			philanthropic drug donation program
1	Pembrolizumab	5775.96	3041.41	2.82	0.09	34754.72	philanthropic drug donation program
2	Chemotherapy	2734.55		2.73			price dropped by 60%
2	Pembrolizumab	16693.97	13959.43	2.82	0.09	159516.66	price dropped by 60%
3	Chemotherapy	2802.98		2.88			3% discount
	Pembrolizumab	40167.86	37364.88	2.97	0.09	410285.33	3% discount
	Chemotherapy	2646.93		2.55			8% discount
	Pembrolizumab	39086.87	36439.94	2.63	0.08	439752.11	8% discount

Incr, incremental ratio; Eff, effectiveness; ICER, incremental cost-effectiveness ratio

ISSN: 1478-7547